HRP20110739T1 - Farmaceutski pripravak za oralno davanje sa kontroliranim otpuštanjem lijeka u tankom crijevu i postupak njegovog dobivanja - Google Patents
Farmaceutski pripravak za oralno davanje sa kontroliranim otpuštanjem lijeka u tankom crijevu i postupak njegovog dobivanja Download PDFInfo
- Publication number
- HRP20110739T1 HRP20110739T1 HR20110739T HRP20110739T HRP20110739T1 HR P20110739 T1 HRP20110739 T1 HR P20110739T1 HR 20110739 T HR20110739 T HR 20110739T HR P20110739 T HRP20110739 T HR P20110739T HR P20110739 T1 HRP20110739 T1 HR P20110739T1
- Authority
- HR
- Croatia
- Prior art keywords
- active substance
- pharmaceutical preparation
- preparation according
- methyl
- methyl methacrylate
- Prior art date
Links
- 210000000813 small intestine Anatomy 0.000 title claims abstract 8
- 239000000825 pharmaceutical preparation Substances 0.000 title claims 27
- 238000000034 method Methods 0.000 title claims 3
- 238000002360 preparation method Methods 0.000 title claims 2
- 210000001072 colon Anatomy 0.000 title 1
- 238000013267 controlled drug release Methods 0.000 title 1
- 239000013543 active substance Substances 0.000 claims abstract 30
- 238000009792 diffusion process Methods 0.000 claims abstract 26
- 229920001577 copolymer Polymers 0.000 claims abstract 25
- 239000004480 active ingredient Substances 0.000 claims abstract 20
- 239000003795 chemical substances by application Substances 0.000 claims abstract 14
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract 8
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract 8
- 150000003839 salts Chemical class 0.000 claims abstract 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract 6
- 239000011159 matrix material Substances 0.000 claims abstract 6
- 230000035699 permeability Effects 0.000 claims abstract 6
- -1 4-diethylamino -2-butynyl Chemical group 0.000 claims abstract 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims abstract 5
- 239000001913 cellulose Substances 0.000 claims abstract 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims abstract 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims abstract 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims abstract 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract 3
- 229930195725 Mannitol Natural products 0.000 claims abstract 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract 3
- 229930006000 Sucrose Natural products 0.000 claims abstract 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract 3
- 229920002678 cellulose Polymers 0.000 claims abstract 3
- 235000010980 cellulose Nutrition 0.000 claims abstract 3
- 235000010944 ethyl methyl cellulose Nutrition 0.000 claims abstract 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims abstract 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000008101 lactose Substances 0.000 claims abstract 3
- 239000000594 mannitol Substances 0.000 claims abstract 3
- 235000010355 mannitol Nutrition 0.000 claims abstract 3
- 229920000609 methyl cellulose Polymers 0.000 claims abstract 3
- 239000001923 methylcellulose Substances 0.000 claims abstract 3
- 235000010981 methylcellulose Nutrition 0.000 claims abstract 3
- 229920003087 methylethyl cellulose Polymers 0.000 claims abstract 3
- 229950008882 polysorbate Drugs 0.000 claims abstract 3
- 229920000136 polysorbate Polymers 0.000 claims abstract 3
- 239000011148 porous material Substances 0.000 claims abstract 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract 3
- 239000000600 sorbitol Substances 0.000 claims abstract 3
- 235000010356 sorbitol Nutrition 0.000 claims abstract 3
- 239000005720 sucrose Substances 0.000 claims abstract 3
- 229920002554 vinyl polymer Polymers 0.000 claims abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract 3
- MWHXMIASLKXGBU-RNCYCKTQSA-N (e)-but-2-enedioic acid;[2-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate Chemical compound OC(=O)\C=C\C(O)=O.C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C(C)C)=CC=CC=C1 MWHXMIASLKXGBU-RNCYCKTQSA-N 0.000 claims abstract 2
- UVKFSMBPRQBNCH-UHFFFAOYSA-M 4,4-diphenylbutan-2-yl-ethyl-dimethylazanium;bromide Chemical compound [Br-].C=1C=CC=CC=1C(CC(C)[N+](C)(C)CC)C1=CC=CC=C1 UVKFSMBPRQBNCH-UHFFFAOYSA-M 0.000 claims abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims abstract 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract 2
- KFUJMHHNLGCTIJ-UHFFFAOYSA-N Propiverine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCCC)C(=O)OC1CC[NH+](C)CC1 KFUJMHHNLGCTIJ-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract 2
- 238000013270 controlled release Methods 0.000 claims abstract 2
- GUBNMFJOJGDCEL-UHFFFAOYSA-N dicyclomine hydrochloride Chemical compound [Cl-].C1CCCCC1C1(C(=O)OCC[NH+](CC)CC)CCCCC1 GUBNMFJOJGDCEL-UHFFFAOYSA-N 0.000 claims abstract 2
- JEJBJBKVPOWOQK-UHFFFAOYSA-N emepronium Chemical compound C=1C=CC=CC=1C(CC(C)[N+](C)(C)CC)C1=CC=CC=C1 JEJBJBKVPOWOQK-UHFFFAOYSA-N 0.000 claims abstract 2
- XOEVKNFZUQEERE-UHFFFAOYSA-N flavoxate hydrochloride Chemical compound Cl.C1=CC=C2C(=O)C(C)=C(C=3C=CC=CC=3)OC2=C1C(=O)OCCN1CCCCC1 XOEVKNFZUQEERE-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract 2
- 229920003124 powdered cellulose Polymers 0.000 claims abstract 2
- 235000019814 powdered cellulose Nutrition 0.000 claims abstract 2
- 229940095064 tartrate Drugs 0.000 claims abstract 2
- JACRWUWPXAESPB-UHFFFAOYSA-M tropate Chemical compound OCC(C([O-])=O)C1=CC=CC=C1 JACRWUWPXAESPB-UHFFFAOYSA-M 0.000 claims abstract 2
- 239000010410 layer Substances 0.000 claims 28
- 239000000969 carrier Substances 0.000 claims 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 6
- 229920002301 cellulose acetate Polymers 0.000 claims 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 235000002639 sodium chloride Nutrition 0.000 claims 6
- 229920002472 Starch Polymers 0.000 claims 5
- 210000003296 saliva Anatomy 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 229920002261 Corn starch Polymers 0.000 claims 4
- 239000001856 Ethyl cellulose Substances 0.000 claims 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 4
- 235000021355 Stearic acid Nutrition 0.000 claims 4
- 239000011230 binding agent Substances 0.000 claims 4
- 239000008120 corn starch Substances 0.000 claims 4
- 229920001249 ethyl cellulose Polymers 0.000 claims 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims 4
- 239000007788 liquid Substances 0.000 claims 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 4
- 239000008117 stearic acid Substances 0.000 claims 4
- 239000000725 suspension Substances 0.000 claims 4
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 3
- 229920008347 Cellulose acetate propionate Polymers 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 229920001800 Shellac Polymers 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims 3
- 239000004359 castor oil Substances 0.000 claims 3
- 235000019438 castor oil Nutrition 0.000 claims 3
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 3
- 239000011248 coating agent Substances 0.000 claims 3
- 239000011247 coating layer Substances 0.000 claims 3
- 238000000576 coating method Methods 0.000 claims 3
- 229940099112 cornstarch Drugs 0.000 claims 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 3
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 3
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 3
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 3
- NZEXUPLJXSDMCK-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O.COC(=O)C(C)=C NZEXUPLJXSDMCK-UHFFFAOYSA-N 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 229920002689 polyvinyl acetate Polymers 0.000 claims 3
- 239000011118 polyvinyl acetate Substances 0.000 claims 3
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 3
- 239000004208 shellac Substances 0.000 claims 3
- 229940113147 shellac Drugs 0.000 claims 3
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims 3
- 235000013874 shellac Nutrition 0.000 claims 3
- 229940100445 wheat starch Drugs 0.000 claims 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- 108010010803 Gelatin Proteins 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 2
- 239000001506 calcium phosphate Substances 0.000 claims 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 2
- 230000007423 decrease Effects 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 150000002191 fatty alcohols Chemical class 0.000 claims 2
- 239000008273 gelatin Substances 0.000 claims 2
- 229920000159 gelatin Polymers 0.000 claims 2
- 229940014259 gelatin Drugs 0.000 claims 2
- 235000019322 gelatine Nutrition 0.000 claims 2
- 235000011852 gelatine desserts Nutrition 0.000 claims 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims 2
- 239000004014 plasticizer Substances 0.000 claims 2
- 229940075065 polyvinyl acetate Drugs 0.000 claims 2
- 229920001592 potato starch Polymers 0.000 claims 2
- 229940100486 rice starch Drugs 0.000 claims 2
- 239000000377 silicon dioxide Substances 0.000 claims 2
- 235000012239 silicon dioxide Nutrition 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 239000000454 talc Substances 0.000 claims 2
- 229910052623 talc Inorganic materials 0.000 claims 2
- 239000011975 tartaric acid Substances 0.000 claims 2
- 235000002906 tartaric acid Nutrition 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims 2
- 150000003626 triacylglycerols Chemical class 0.000 claims 2
- GNWCZBXSKIIURR-UHFFFAOYSA-N (2-docosanoyloxy-3-hydroxypropyl) docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCCCCCC GNWCZBXSKIIURR-UHFFFAOYSA-N 0.000 claims 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 claims 1
- 239000005995 Aluminium silicate Substances 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- VBCPVIWPDJVHAN-UHFFFAOYSA-N Phenoxybenzamine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C[NH+](CCCl)C(C)COC1=CC=CC=C1 VBCPVIWPDJVHAN-UHFFFAOYSA-N 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- 239000004902 Softening Agent Substances 0.000 claims 1
- RXZMMZZRUPYENV-VROPFNGYSA-N Solifenacin succinate Chemical compound OC(=O)CCC(O)=O.C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 RXZMMZZRUPYENV-VROPFNGYSA-N 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000001361 adipic acid Substances 0.000 claims 1
- 235000011037 adipic acid Nutrition 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 235000012211 aluminium silicate Nutrition 0.000 claims 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims 1
- 235000019568 aromas Nutrition 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000012928 buffer substance Substances 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000012876 carrier material Substances 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- 235000019700 dicalcium phosphate Nutrition 0.000 claims 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims 1
- 229940038472 dicalcium phosphate Drugs 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- XIQVNETUBQGFHX-JOCHJYFZSA-N esoxybutynin Chemical compound C1([C@@](O)(C(=O)OCC#CCN(CC)CC)C=2C=CC=CC=2)CCCCC1 XIQVNETUBQGFHX-JOCHJYFZSA-N 0.000 claims 1
- XPNLOZNCOBKRNJ-UHFFFAOYSA-N ethyl prop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C=C.COC(=O)C(C)=C XPNLOZNCOBKRNJ-UHFFFAOYSA-N 0.000 claims 1
- 235000013312 flour Nutrition 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims 1
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 claims 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims 1
- 239000001087 glyceryl triacetate Substances 0.000 claims 1
- 235000013773 glyceryl triacetate Nutrition 0.000 claims 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims 1
- 239000004816 latex Substances 0.000 claims 1
- 229920000126 latex Polymers 0.000 claims 1
- 229960003511 macrogol Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 229940057917 medium chain triglycerides Drugs 0.000 claims 1
- 239000004200 microcrystalline wax Substances 0.000 claims 1
- 235000019808 microcrystalline wax Nutrition 0.000 claims 1
- 235000019426 modified starch Nutrition 0.000 claims 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 229940116317 potato starch Drugs 0.000 claims 1
- 235000013772 propylene glycol Nutrition 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 229920002379 silicone rubber Polymers 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 229960001790 sodium citrate Drugs 0.000 claims 1
- 235000011083 sodium citrates Nutrition 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- 239000004408 titanium dioxide Substances 0.000 claims 1
- 229960002622 triacetin Drugs 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 235000019731 tricalcium phosphate Nutrition 0.000 claims 1
- 229940078499 tricalcium phosphate Drugs 0.000 claims 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims 1
- 239000001069 triethyl citrate Substances 0.000 claims 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 1
- 235000013769 triethyl citrate Nutrition 0.000 claims 1
- 239000001993 wax Substances 0.000 claims 1
- 229940045860 white wax Drugs 0.000 claims 1
- 239000012530 fluid Substances 0.000 abstract 2
- XIQVNETUBQGFHX-QFIPXVFZSA-N (R)-oxybutynin Chemical compound C1([C@](O)(C(=O)OCC#CCN(CC)CC)C=2C=CC=CC=2)CCCCC1 XIQVNETUBQGFHX-QFIPXVFZSA-N 0.000 abstract 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 abstract 1
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 abstract 1
- 239000000679 carrageenan Substances 0.000 abstract 1
- 235000010418 carrageenan Nutrition 0.000 abstract 1
- 229920001525 carrageenan Polymers 0.000 abstract 1
- 229940113118 carrageenan Drugs 0.000 abstract 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 abstract 1
- 230000002497 edematous effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Farmaceutski pripravak za oralno davanje sa kontroliranim otpuštanjem aktivne tvari u tankom crijevu, na temelju nosača aktivnog sastojka koji dolazi uz barem jedan aktivni sastojak koji ima unutarnji sloj radi kontrole otpuštanja aktivnog sastojka i sa gastro-otpornim slojem kojim je prevučen preko njega, naznačen time da je unutarnji sloj formiran od najmanje dva difuzijska sloja čija se permeabilnost za difuziju aktivnog sastojka smanjuje iznutra prema van, difuzijski slojevi su formirani od matričnog materijala koji je netopiv u tekućini tankog crijeva i u koji su uključena sredstava za stvaranje pora koja kontroliraju permeabilnost za difuziju aktivnog sastojka i koja sredstva su topiva i/ili bubriva i/ili mogu apsorbirati vodu u tekućini tankog crijeva te time da su sredstava za stvaranje pora difuzijskih slojeva odabrana iz skupine koju čine polivinil alkohol-polietilen glikol kopolimeri, polivinilpirolidon, vinilpirolidon-vinil acetat kopolimeri, umreženi polivinilpirolidon, mikrokristalna celuloza, hidroksipropilceluloza, natrij karboksimetilceluloza, metilceluloza, hidroksietilceluloza, metiletilceluloza, metilhidroksipropilceluloza, hidroksipropilmetilceluloza, hidroksietilmetilpropilceluloza, polietilen glikol, celuloza u prahu, sukroza, laktoza, manitol, sorbitol i polisorbat, te time da nosač aktivnog sastojka sadrži kao aktivni sastojak 4-dietilamino-2-butinil α-fenilcikloheksanglikonat hidroklorid, etildimetil(1-metil-3,3-difenilpropil)amonij karagenat, (+)-[R-2-[α-2-(diizopropilamino)etil]benzil]-p-kresol tartrat, 8-(ciklopropilmetil)-6?,7?-epoksi-3α-hidroksi-1αH,5α)-(S)-tropat bromid, (1R,3r,5S)-3-[(hidroksildifenilacetil)oksi]spiro[8-azoniabiciklo[3.2.1]oktan-8,1'-pirolidinij] klorid, 2-dietilaminoetil (bicikloheksil)-1-karboksilat hidroklorid, 1-metil-4-piperidil difenilpropoksiacetat hidroklorid, (3R)-1-azabiciklo[2.2.2]okt-3-il (1S)-1-fenil-3,4-dihidroizokinolin-2(1H)-karboksilat sukcinat, (S)-1-[2-(2,3-dihidro-5-benzofuranil)etil]-α,α-difenil-3-pirolidineacetamid hidrobromid, (8R)-3α-hidroksi-5-izopropil-1αH, 5αH-tropanij bromid (±tropat), 8-butil-6?,7?-epoksi-3α-[(S)-3-hidroksi-2-fenilpropanoiloksi]tropanij bromid, (+)-(S)-N-metil-il-(1-naftiloksi)-2-tiofenpropilamin, 2-[(1R)-3-(diizopropilamino)-1-fenilpropil]-4-(hidroksimetil)fenil izobutirat, 4-(dietilamino)-but-2-in-1-il (2S)-cikloheksil(hidroksi)fenilacetat, etildimetil(1-metil-3,3-difenilpropil)amonij bromid, 2-piperidinoetil 3-metil-4-okso-2-fenil-4H-kromen-8-karboksilat hidroklorid, benzil(2-kloroetil)(1-metil-2-fenoksietil)amin hidroklorid i/ili sol ili druga sol tih aktivnih sastojaka. Patent sadrži još 25 patentnih zahtjeva.
Claims (26)
1. Farmaceutski pripravak za oralno davanje sa kontroliranim otpuštanjem aktivne tvari u tankom crijevu, na temelju nosača aktivnog sastojka koji dolazi uz barem jedan aktivni sastojak koji ima unutarnji sloj radi kontrole otpuštanja aktivnog sastojka i sa gastro-otpornim slojem kojim je prevučen preko njega, naznačen time da je unutarnji sloj formiran od najmanje dva difuzijska sloja čija se permeabilnost za difuziju aktivnog sastojka smanjuje iznutra prema van, difuzijski slojevi su formirani od matričnog materijala koji je netopiv u tekućini tankog crijeva i u koji su uključena sredstava za stvaranje pora koja kontroliraju permeabilnost za difuziju aktivnog sastojka i koja sredstva su topiva i/ili bubriva i/ili mogu apsorbirati vodu u tekućini tankog crijeva te time da su sredstava za stvaranje pora difuzijskih slojeva odabrana iz skupine koju čine polivinil alkohol-polietilen glikol kopolimeri, polivinilpirolidon, vinilpirolidon-vinil acetat kopolimeri, umreženi polivinilpirolidon, mikrokristalna celuloza, hidroksipropilceluloza, natrij karboksimetilceluloza, metilceluloza, hidroksietilceluloza, metiletilceluloza, metilhidroksipropilceluloza, hidroksipropilmetilceluloza, hidroksietilmetilpropilceluloza, polietilen glikol, celuloza u prahu, sukroza, laktoza, manitol, sorbitol i polisorbat, te time da nosač aktivnog sastojka sadrži kao aktivni sastojak 4-dietilamino-2-butinil α-fenilcikloheksanglikonat hidroklorid, etildimetil(1-metil-3,3-difenilpropil)amonij karagenat, (+)-[R-2-[α-2-(diizopropilamino)etil]benzil]-p-kresol tartrat, 8-(ciklopropilmetil)-6β,7β-epoksi-3α-hidroksi-1αH,5α)-(S)-tropat bromid, (1R,3r,5S)-3-[(hidroksildifenilacetil)oksi]spiro[8-azoniabiciklo[3.2.1]oktan-8,1'-pirolidinij] klorid, 2-dietilaminoetil (bicikloheksil)-1-karboksilat hidroklorid, 1-metil-4-piperidil difenilpropoksiacetat hidroklorid, (3R)-1-azabiciklo[2.2.2]okt-3-il (1S)-1-fenil-3,4-dihidroizokinolin-2(1H)-karboksilat sukcinat, (S)-1-[2-(2,3-dihidro-5-benzofuranil)etil]-α,α-difenil-3-pirolidineacetamid hidrobromid, (8R)-3α-hidroksi-5-izopropil-1αH, 5αH-tropanij bromid (±tropat), 8-butil-6β,7β-epoksi-3α-[(S)-3-hidroksi-2-fenilpropanoiloksi]tropanij bromid, (+)-(S)-N-metil-il-(1-naftiloksi)-2-tiofenpropilamin, 2-[(1R)-3-(diizopropilamino)-1-fenilpropil]-4-(hidroksimetil)fenil izobutirat, 4-(dietilamino)-but-2-in-1-il (2S)-cikloheksil(hidroksi)fenilacetat, etildimetil(1-metil-3,3-difenilpropil)amonij bromid, 2-piperidinoetil 3-metil-4-okso-2-fenil-4H-kromen-8-karboksilat hidroklorid, benzil(2-kloroetil)(1-metil-2-fenoksietil)amin hidroklorid i/ili sol ili druga sol tih aktivnih sastojaka.
2. Farmaceutski pripravak prema zahtjevu 1, naznačen time da difuzijski slojevi sadrže matrične materijale koji su identični ili različitih vrsta.
3. Farmaceutski pripravak prema barem jednom od zahtjeva 1 i 2, naznačen time da difuzijski slojevi sadrže jedno ili više sredstava za stvaranje pora koja su identična ili različitih vrsta.
4. Farmaceutski pripravak prema barem jednom od prethodnih zahtjeva, naznačen time da je permeabilnost difuzijskih slojeva za difuziju aktivnog sastojka kontrolirana pomoću prirode, količine i/ili veličine čestica i/ili topivosti i/ili bubrivosti i/ili kapaciteta absorpcije vode sredstava za stvaranje pora.
5. Farmaceutski pripravak prema zahtjevu 4, naznačen time da unutarnji sloj za kontroliranje otpuštanja aktivnog sastojka uključuje unutarnji i vanjski difuzijski sloj.
6. Farmaceutski pripravak prema zahtjevu 5, naznačen time da je u slučaju identičnog materijala za stvaranje pora veličina čestica i/ili koncentracija sredstva za stvaranje pora u unutarnjem difuzijskom sloju veća nego u vanjskom difuzijskom sloju.
7. Farmaceutski pripravak prema zahtjevu 6, naznačen time da je u slučaju sredstava za stvaranje pora koja su topiva u tekućini tankog crijeva, omjer koncentracije sredstva za stvaranje pora u unutrašnjem difuzijskom sloju prema koncentraciji sredstva za stvaranje pora u vanjskom difuzijskom sloju je u rasponu od 20:1 do > 1:1, poželjno 10:1 do 1.1:1.
8. Farmaceutski pripravak prema barem jednom od prethodnih zahtjeva, naznačen time je matrični materijal difuzijskih slojeva odabran iz skupine koja sadrži etilcelulozu, celuloza acetat ftalat, celuloza acetat sukcinat, šelak, hidroksipropilmetilceluloza acetat sukcinat, celuloza acetat, celuloza acetat propionat, hidroksipropilmetilceluloza ftalat, polivinil acetat, polivinil acetat ftalat, celuloza acetat butirat, butil metakrilat-(2-dimetilaminoetil) metakrilat-metil metakrilat kopolimere, etil akrilat-metil metakrilat kopolimere, metakrilna kiselina-metil metakrilat kopolimere, metakrilna kiselina-etil akrilat kopolimere, etil akrilat-metil metakrilat-trimetil-amonijetil metakrilat klorid kopolimere, kitosan, silikon elastomerne lateks suspenzije, hidrogenizirano ricinusovo ulje, stearinsku kiselinu, glicerol monostearat, glicerol distearat, glicerol dibehenat, stearil alkohol, bijeli vosak, žuti vosak, hidrogenizirano biljno ulje i mikrokristalni vosak.
9. Farmaceutski pripravak prema barem jednom od prethodnih zahtjeva, naznačen time da matrični materijal difuzijskih slojeva dodatno sadrži plastifikatore i sredstva za odvajanje.
10. Farmaceutski pripravak prema zahtjevu 9, naznačen time da matrični materijal difuzijskih slojeva kao sredstvo za omekšavanje sadrži polietilen glikol, propilen glikol, trietil citrat, triacetin, acetil tributil citrat, polisorbat, 2-pirolidon, dibutil sebakat, stearinsku kiselinu, ricinusovo ulje i/ili srednjelančane trigliceride kao plastifikator, te talk, stearinsku kiselinu i njene soli, masne alkohole, mono-, di- ili trigliceride sa ravnim- i/ili razgranatim-lančastim masnim kiselinama, koloidni silicij dioksid, taloženi silicij dioksid, aluminij oksid, kaolin, kukuruzni škrob, pšenični škrob, rižino brašno, krumpirov škrob, titanij dioksid, silikonske emulzije i/ili Veegum (magnezij aluminij silikatna disperzija).
11. Farmaceutski pripravak prema zahtjevu 10, naznačen time da je aktivna tvar prisutna u količini od 1 do 250 mg po jedinici doziranja na nosačima aktivne tvari.
12. Farmaceutski pripravak prema zahtjevu 10 ili 13, naznačen time da je aktivna tvar prisutna u obliku premaza na nosačima aktivne tvari.
13. Farmaceutski pripravak prema barem jednom od prethodnih zahtjeva, naznačen time da su nosači aktivne tvari u obliku neutralnih peleta i/ili kristalnih tvari i/ili granuliranih ili ekstrudiranih tvari kao nosača.
14. Farmaceutski pripravak prema zahtjevu 13, naznačen time da nosači aktivne tvari imaju veličinu čestica od 0.1 do 3.0 mm.
15. Farmaceutski pripravak prema zahtjevu 13 ili 14, naznačen time da nosači aktivne tvari uključuju kao materijal nosača šećer, škrob, mikrokristalnu celulozu, dikalcijev fosfat, natrij klorid, limunsku kiselinu, vinsku kiselinu, maleinsku kiselinu, sukrozu, laktozu, sorbitol, manitol, celulozu, kalcij hidrogen fosfat, natrij citrat, trikalcijev fosfat, kukuruzni škrob, pšenični škrob, krumpirov škrob, rižin škrob i/ili njihove mješavine.
16. Farmaceutski pripravak prema barem jednom od prethodnih zahtjeva, naznačen time da nosači aktivne tvari koji dolaze uz aktivnu tvar dodatno, pored aktivne tvari, imaju na njihovoj površini vezivo, te tamo gdje je prikladno sredstvo za odvajanje i/ili puferske tvari.
17. Farmaceutski pripravak prema zahtjevu 16, naznačen time da nosači aktivne tvari koji dolaze uz aktivnu tvar sadrže po jedinici doziranja od 1 do 250 mg aktivnog sastojka, od 10 do 500 dijelova težinski materijala nosača, od 1 do 100 dijelova težinski veziva, od 1 do 100 dijelova težinski sredstva za odvajanje i od 1 do 100 dijelova težinski puferske tvari.
18. Farmaceutski pripravak prema zahtjevima 16 i 17, naznačen time da su vezivna sredstva nosača aktivne tvari koja dolaze uz aktivnu tvar odabrana iz skupine koja sadrži hidroksipropilmetilcelulozu, butil metakrilat-(2-dimetilaminoetil) metakrilat-metil metakrilat kopolimere, etil akrilat-metil metakrilat kopolimere, metakrilna kiselina-metil metakrilat kopolimere, metakrilna kiselina-etil akrilat kopolimere, metil akrilat-metil metakrilat-metakrilna kiselina kopolimere, etil akrilat-metil metakrilat-trimetilamonijetil metakrilat klorid kopolimere, etilcelulozu, natrij karboksimetilcelulozu, metilcelulozu, hidroksietilcelulozu, metiletilcelulozu, hidroksietilmetilpropilcelulozu, polivinilpirolidon, polivinil acetat, vinilpirolidon-vinil acetat kopolimere, polietilen glikol, želatinu, kukuruzni škrob, pšenični škrob, rižin škrob i kukuruzni škrob i njihove mješavine.
19. Farmaceutski pripravak prema zahtjevima 16 do 18, naznačen time da je sredstvo za odvajanje nosača aktivne tvari koje dolazi uz aktivnu tvar odabrano iz skupine koja sadrži talk, stearinsku kiselinu i njene soli, mono-, di-, trigliceride sa ravnim- i/ili razgranatim-lancem masnih kiselina, masne alkohole, koloidni silicij dioksid, taloženi silicij dioksid, aluminij oksid, hidrogenizirano ricinusovo ulje, te makrogol (polietilen glikol) i njihove mješavine.
20. Farmaceutski pripravak prema zahtjevima 16 do 19, naznačen time da su puferske tvari nosača aktivne tvari koji dolaze uz aktivnu tvar odabrane iz skupine koja sadrži natrij hidroksid, limunsku kiselinu, vinsku kiselinu, fosfornu kiselinu, askorbinsku kiselinu, sukcinsku kiselinu, adipinsku kiselinu, fumarnu kiselinu i njihove farmaceutski prihvatljive soli i njihove mješavine.
21. Farmaceutski pripravak prema barem jednom od prethodnih zahtjeva, naznačen time da je gastro-otporni sloj prevlake položen na nosač aktivne tvari koji dolazi uz aktivnu tvar i difuzijski slojevi su formirani iz skupine koja sadrži etilcelulozu, celuloza acetat ftalat, celuloza acetat sukcinat, šelak, hidroksipropilmetilceluloza acetat sukcinat, celuloza acetat, celuloza acetat propionat, hidroksipropilmetilceluloza ftalat, polivinil acetat ftalat, celuloza acetat butirat, butil metakrilat-(2-dimetilaminoetil metakrilat-metil metakrilat kopolimer, etil akrilat-metil metakrilat kopolimer, metakrilna kiselina-metil metakrilat kopolimer, metakrilna kiselina-etil akrilat kopolimer, metakrilna kiselina-metil metakrilat kopolimer, metil akrilat-metil metakrilat-metakrilna kiselina kopolimer, etil akrilat-metil metakrilat-trimetilaminoetil metakrilat klorid kopolimer i/ili njihove mješavine.
22. Farmaceutski pripravak prema barem jednom od prethodnih zahtjeva, naznačen time da nosači aktivne tvari koji dolaze uz aktivnu tvar, difuzijski slojevi i tamo gdje je prikladno gastro-otporni premaz dolaze sa vanjskim slojem koji je otporan na slinu.
23. Farmaceutski pripravak prema zahtjevu 22, naznačen time nosači aktivne tvari koji dolaze uz aktivnu tvar, difuzijski slojevi i tamo gdje je prikladno gastro-otporni premaz dolaze sa vanjskim slojem koji je otporan na slinu iz skupine koja sadrži etilcelulozu, celuloza acetat ftalat, celuloza acetat sukcinat, šelak, hidroksipropilmetilceluloza acetat sukcinat, celuloza acetat, celuloza acetat propionat, hidroksipropilmetilceluloza ftalat, polivinil acetat, polivinil acetat ftalat, polivinil alkohol-polietilen glikol kopolimer, celuloza acetat butirat, butil metakrilat-2-dimetilaminoetil metakrilat-metil metakrilat kopolimer, etil akrilat-metil metakrilat kopolimer, metakrilna kiselina-metil metakrilat kopolimer, metakrilna kiselina-etil akrilat kopolimer, metakrilna kiselina-metil metakrilat kopolimer, metil akrilat-metil metakrilat-metakrilna kiselina kopolimer, etil akrilat-metil metakrilat-trimetilaminoetil metakrilat klorid kopolimer i/ili njihove mješavine.
24. Farmaceutski pripravak prema zahtjevu 23, naznačen time da vanjski sloj koji je otporan na slinu sadrži aromatične tvari, arome i/ili zaslađivače.
25. Farmaceutski pripravak prema barem jednom od prethodnih zahtjeva, naznačen time da su nosači aktivne tvari koji dolaze uz aktivnu tvar, difuzijski slojevi, gastro-otporni sloj premaza, te tamo gdje je prikladno, vanjski sloj koji je otporan na slinu, komprimirani u tablete korištenjem uobičajenih pomoćnih tvari, ili su pakirani u kapsule izrađene od želatine, celuloze, škroba ili derivata škroba, ili su u obliku tekućina ili polu krutom obliku ili kruti pripravci za pripremanje suspenzije ili suspenzijskog gela.
26. Postupak za dobivanje farmaceutskog pripravka prema zahtjevima 1 do 25, naznačen time, da koristeći ranije poznate procedure, nosači aktivne tvari se prevlače sa otopinom ili suspenzijom koja sadrži aktivnu tvar, vezivo, sredstvo za odvajanje, te gdje je prikladno, puferske tvari, onda se uspješno primjenjuju barem dva difuzijska sloja čija se permeabilnost za difuziju aktivnog sastojka smanjuje iznutra prema van, primjenjuje se gastro-otporni sloj premaza, te gdje je prikladno predviđen je i vanjski sloj koji je otporan na slinu.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06014244A EP1880718B1 (de) | 2006-07-10 | 2006-07-10 | Pharmazeutische Zubereitung für die orale Verabreichung mit gesteuerter Wirkstofffreisetzung im Dünndarm und Verfahren zu ihrer Herstellung |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20110739T1 true HRP20110739T1 (hr) | 2011-11-30 |
Family
ID=37496994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110739T HRP20110739T1 (hr) | 2006-07-10 | 2011-10-12 | Farmaceutski pripravak za oralno davanje sa kontroliranim otpuštanjem lijeka u tankom crijevu i postupak njegovog dobivanja |
Country Status (22)
Country | Link |
---|---|
US (2) | US8221787B2 (hr) |
EP (1) | EP1880718B1 (hr) |
JP (1) | JP5424877B2 (hr) |
KR (1) | KR101451233B1 (hr) |
CN (1) | CN101495103B (hr) |
AR (1) | AR061860A1 (hr) |
AT (1) | ATE525065T1 (hr) |
CA (1) | CA2655838C (hr) |
CL (1) | CL2007002000A1 (hr) |
DK (1) | DK1880718T3 (hr) |
EA (1) | EA016683B1 (hr) |
ES (1) | ES2374158T3 (hr) |
HK (1) | HK1109858A1 (hr) |
HR (1) | HRP20110739T1 (hr) |
IL (1) | IL195931A (hr) |
JO (1) | JO2801B1 (hr) |
MX (1) | MX2009000379A (hr) |
PL (1) | PL1880718T3 (hr) |
SI (1) | SI1880718T1 (hr) |
TW (1) | TWI375573B (hr) |
UA (1) | UA95805C2 (hr) |
WO (1) | WO2008006506A1 (hr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009130712A2 (en) * | 2008-04-22 | 2009-10-29 | Lupin Limited | Controlled release pharmaceutical compositions of trospium |
EP2133072A1 (en) | 2008-06-13 | 2009-12-16 | KRKA, D.D., Novo Mesto | Gastro-resistant pharmaceutical oral compositions comprising duloxetine or its pharmaceutically acceptable derivatives |
WO2010043408A2 (de) * | 2008-10-17 | 2010-04-22 | Ratiopharm Gmbh | Mikroverkapseltes fesoterodin |
DE102009001636A1 (de) * | 2009-03-18 | 2010-09-23 | Henkel Ag & Co. Kgaa | Bleichmittel mit verzögertem Bleichbeginn |
US20100303920A1 (en) * | 2009-05-27 | 2010-12-02 | Johan Hjartstam | Aqueous Film Coating Composition / 841 |
RU2014109079A (ru) * | 2011-08-12 | 2015-09-20 | Бёрингер Ингельхайм Ветмедика Гмбх | Фармацевтическая композиция с маскированным вкусом |
WO2013090893A1 (en) * | 2011-12-16 | 2013-06-20 | Celanese Eva Performance Polymers, Inc. | Gastroretentive controlled release vehicles that include ethylene copolymers, ethyl celluloses, and/or thermpoplastic polyurethanes |
JP2013145174A (ja) * | 2012-01-13 | 2013-07-25 | Panasonic Corp | 近接センサ |
PL2958607T3 (pl) * | 2013-05-02 | 2016-12-30 | Powłoka cewnika balonowego | |
JP6168673B2 (ja) * | 2015-10-07 | 2017-07-26 | 協和発酵キリン株式会社 | アリールアルキルアミン化合物含有医薬組成物 |
ITUA20161799A1 (it) * | 2016-03-18 | 2017-09-18 | Recordati Ind Chimica E Farmaceutica S P A | Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI101344B1 (fi) * | 1988-03-31 | 1998-06-15 | Tanabe Seiyaku Co | Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta |
US5840329A (en) * | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
ES2168043B1 (es) * | 1999-09-13 | 2003-04-01 | Esteve Labor Dr | Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido. |
JP3888064B2 (ja) * | 2000-01-27 | 2007-02-28 | 田辺製薬株式会社 | 徐放性製剤およびその製法 |
US20030018061A1 (en) * | 2000-01-28 | 2003-01-23 | Kohei Ogawa | Novel remedies with the use of beta 3 agonist |
DE10013029A1 (de) * | 2000-03-17 | 2001-09-20 | Roehm Gmbh | Mehrschichtige Arzneiform für die Colonfreigabe |
IN192159B (hr) * | 2000-05-15 | 2004-02-28 | Ranbaxy Lab Ltd | |
US7229665B2 (en) * | 2001-05-22 | 2007-06-12 | Millipore Corporation | Process of forming multilayered structures |
TR200300510A2 (tr) * | 2003-04-18 | 2004-11-22 | Sanovel �La� Sanay� Ve T�Caret A.�. | Dağılan alendronat mikropartikül formülasyonu |
DK2210605T3 (en) * | 2003-11-04 | 2017-05-22 | Tcd Royalty Sub Llc | Daily single dose doses of trospium. |
JP4771956B2 (ja) * | 2003-11-04 | 2011-09-14 | スパーナス ファーマシューティカルズ インコーポレイテッド | バイオアベイラビリティーエンハンサを含む第四級アンモニウム化合物の組成物 |
-
2006
- 2006-07-10 DK DK06014244.5T patent/DK1880718T3/da active
- 2006-07-10 AT AT06014244T patent/ATE525065T1/de active
- 2006-07-10 PL PL06014244T patent/PL1880718T3/pl unknown
- 2006-07-10 ES ES06014244T patent/ES2374158T3/es active Active
- 2006-07-10 SI SI200631131T patent/SI1880718T1/sl unknown
- 2006-07-10 EP EP06014244A patent/EP1880718B1/de active Active
-
2007
- 2007-06-27 TW TW096123213A patent/TWI375573B/zh not_active IP Right Cessation
- 2007-07-05 MX MX2009000379A patent/MX2009000379A/es active IP Right Grant
- 2007-07-05 JP JP2009518762A patent/JP5424877B2/ja not_active Expired - Fee Related
- 2007-07-05 UA UAA200900169A patent/UA95805C2/uk unknown
- 2007-07-05 EA EA200970100A patent/EA016683B1/ru not_active IP Right Cessation
- 2007-07-05 KR KR1020097002668A patent/KR101451233B1/ko not_active IP Right Cessation
- 2007-07-05 WO PCT/EP2007/005970 patent/WO2008006506A1/de active Application Filing
- 2007-07-05 CA CA2655838A patent/CA2655838C/en not_active Expired - Fee Related
- 2007-07-05 CN CN200780026301XA patent/CN101495103B/zh not_active Expired - Fee Related
- 2007-07-05 US US12/309,198 patent/US8221787B2/en not_active Expired - Fee Related
- 2007-07-08 JO JO2007271A patent/JO2801B1/en active
- 2007-07-09 CL CL2007002000A patent/CL2007002000A1/es unknown
- 2007-07-10 AR ARP070103054A patent/AR061860A1/es unknown
-
2008
- 2008-04-09 HK HK08103960.2A patent/HK1109858A1/xx not_active IP Right Cessation
- 2008-12-15 IL IL195931A patent/IL195931A/en not_active IP Right Cessation
-
2011
- 2011-10-12 HR HR20110739T patent/HRP20110739T1/hr unknown
-
2012
- 2012-06-15 US US13/525,029 patent/US20120294938A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AR061860A1 (es) | 2008-09-24 |
CA2655838C (en) | 2014-04-08 |
CN101495103A (zh) | 2009-07-29 |
JO2801B1 (en) | 2014-03-15 |
CN101495103B (zh) | 2013-05-22 |
EA016683B1 (ru) | 2012-06-29 |
IL195931A0 (en) | 2009-09-01 |
JP2009542742A (ja) | 2009-12-03 |
EP1880718B1 (de) | 2011-09-21 |
IL195931A (en) | 2014-02-27 |
JP5424877B2 (ja) | 2014-02-26 |
ES2374158T3 (es) | 2012-02-14 |
WO2008006506A1 (de) | 2008-01-17 |
US8221787B2 (en) | 2012-07-17 |
DK1880718T3 (da) | 2011-11-21 |
ATE525065T1 (de) | 2011-10-15 |
CA2655838A1 (en) | 2008-01-17 |
KR20090029830A (ko) | 2009-03-23 |
SI1880718T1 (sl) | 2011-11-30 |
MX2009000379A (es) | 2009-04-14 |
KR101451233B1 (ko) | 2014-10-15 |
PL1880718T3 (pl) | 2012-02-29 |
US20120294938A1 (en) | 2012-11-22 |
UA95805C2 (uk) | 2011-09-12 |
TWI375573B (en) | 2012-11-01 |
HK1109858A1 (en) | 2008-06-27 |
CL2007002000A1 (es) | 2008-01-18 |
TW200808381A (en) | 2008-02-16 |
EA200970100A1 (ru) | 2009-06-30 |
EP1880718A1 (de) | 2008-01-23 |
US20090285891A1 (en) | 2009-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20110739T1 (hr) | Farmaceutski pripravak za oralno davanje sa kontroliranim otpuštanjem lijeka u tankom crijevu i postupak njegovog dobivanja | |
CA2348090C (en) | Oral pulsed dose drug delivery system | |
JP6561105B2 (ja) | 過活動膀胱の治療のための医薬製剤 | |
IL143899A (en) | Controlled release of galanthamine preparation | |
CA2539982A1 (en) | Pantoprazole multiparticulate formulations | |
CA3107139C (en) | Extended release compositions comprising trihexyphenidyl | |
CA2905011C (en) | Extended-release topiramate capsules | |
US20080069870A1 (en) | Controlled Release Compositions Comprising a Cephalosporin for the Treatment of a Bacterial Infection | |
CA2706730C (en) | Single layered controlled release therapeutic system | |
CA3216303A1 (en) | Capsule for specific drug delivery and preparation method therefor | |
AU2004200325B2 (en) | Oral Pulsed Dose Drug Delivery System | |
AU2006236052B2 (en) | Oral pulsed dose drug delivery system | |
EA044924B1 (ru) | Способ получения многоэлементной пероральной дозированной лекарственной формы с модифицированным высвобождением сукцината доксиламина и гидрохлорида пиридоксина | |
WO2019134971A1 (en) | Encapsulated particles comprising a pharmaceutically active ingredient |